SynthesisBritish journal of cancer2015

Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis.

Feng-Che Kuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.